Crizotinib Holds Promise For Lung Cancer, And For Pfizer Oncology

The targeted ALK inhibitor is on an accelerated track, with initial Phase I unveiled at ASCO annual meeting and a registration program already under way.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet